Cardiac hypertrophy and fibrosis

April 30, 2019

Bariatric surgery for safeguarding your heart against cardiac dysfunction: Bariatric surgery, a gastrointestinal surgery for weight loss, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 30/April/2019, 11.48 pm

Bariatric surgery for safeguarding your heart against cardiac dysfunction: Bariatric surgery, a gastrointestinal surgery for weight loss, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 30/April/2019, 11.48 pm https://genomediscovery.org/wp-content/uploads/2019/04/Bariatric-surgery-increases-cardiomyocyte-proliferation.regeneration-enhances-cardiac-contractility-and-attenuates-pathogenesis-associated-with-myocardial-infarction-1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Bariatric-surgery-increases-cardiomyocyte-proliferation.regeneration-enhances-cardiac-contractility-and-attenuates-pathogenesis-associated-with-myocardial-infarction-1.jpg April 30, 2019 April 30, 2019

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

April 9, 2019

Carvedilol-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Carvedilol (Brand name: Coreg), a non-selective beta blocker used to treat congestive heart failure, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, , 9/April/2019, 11.17 pm

Carvedilol-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Carvedilol (Brand name: Coreg), a non-selective beta blocker used to treat congestive heart failure, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, , 9/April/2019, 11.17 pm https://genomediscovery.org/wp-content/uploads/2019/04/Carvedilol-promotes-Cardiomyocyte-CM-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Carvedilol-promotes-Cardiomyocyte-CM-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.jpg2_.jpg April 9, 2019 May 19, 2019

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

April 9, 2019

Intracardiac injection of Lansoprazole promotes heart regeneration and repair: Intracardiac injection of Lansoprazole (trade name: Prevacid) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 9/April/2019, 11.00 pm

Intracardiac injection of Lansoprazole promotes heart regeneration and repair: Intracardiac injection of Lansoprazole (trade name: Prevacid) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 9/April/2019, 11.00 pm https://genomediscovery.org/wp-content/uploads/2019/04/Lanzoprazole-increases-cardiomyocyte-proliferation.regeneration-enhances-cardiac-contractility-and-attenuates-pathogenesis-associated-with-myocardial-infarction.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Lanzoprazole-increases-cardiomyocyte-proliferation.regeneration-enhances-cardiac-contractility-and-attenuates-pathogenesis-associated-with-myocardial-infarction.jpg April 9, 2019 April 9, 2019

April 8, 2019

Molecular therapy for cardiac dysfunction: Lansoprazole (trade name: Prevacid), a medication used to decrease stomach acid secretion, decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 8/April/2018, 11.14 pm

Molecular therapy for cardiac dysfunction: Lansoprazole (trade name: Prevacid), a medication used to decrease stomach acid secretion, decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 8/April/2018, 11.14 pm https://genomediscovery.org/wp-content/uploads/2019/04/Lanzoprazole-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29-and-up-regulation-of-GSK3B-ICAT.CTNNBIP1-and-GLIS2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Lanzoprazole-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29-and-up-regulation-of-GSK3B-ICAT.CTNNBIP1-and-GLIS2.jpg April 8, 2019 April 8, 2019

Introduction: What they say: A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich…

April 1, 2019

Intracardiac injection of Cyclic helix B peptide(CHBP) protects against cardiac hypertrophy and fibrosis: Intracardiac injection of Cyclic helix B peptide(CHBP), a peptide derived from Erythropoietin/Hematopoietin, decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 1/April/2019, 11.33pm

Intracardiac injection of Cyclic helix B peptide(CHBP) protects against cardiac hypertrophy and fibrosis: Intracardiac injection of Cyclic helix B peptide(CHBP), a peptide derived from Erythropoietin/Hematopoietin, decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 1/April/2019, 11.33pm https://genomediscovery.org/wp-content/uploads/2019/04/Cyclic-helix-B-peptideCHBP-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29-and-up-regulation-of-GSK3B-ICAT.CTNNBIP1-HBP1-and-GLIS2.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Cyclic-helix-B-peptideCHBP-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29-and-up-regulation-of-GSK3B-ICAT.CTNNBIP1-HBP1-and-GLIS2.jpg2_.jpg April 1, 2019 April 1, 2019

March 26, 2019

Intracardiac injection of Erythropoietin/Hematopoietin protects against cardiac hypertrophy and fibrosis: Intracardiac injection of erythropoietin/hematopoietin decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 26/March/2019, 11.13 pm

Intracardiac injection of Erythropoietin/Hematopoietin protects against cardiac hypertrophy and fibrosis: Intracardiac injection of erythropoietin/hematopoietin decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 26/March/2019, 11.13 pm https://genomediscovery.org/wp-content/uploads/2019/03/Intracardiac.Epicardial-injection-of-Erythropoietin-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Intracardiac.Epicardial-injection-of-Erythropoietin-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29.jpg March 26, 2019 March 26, 2019

Popular Post